Gary L. Johnson, Ph.D.
Affiliations: | Pharmacology | University of Colorado, Boulder, Boulder, CO, United States |
Website:
http://www.med.unc.edu/pharm/people/primaryfaculty/gary-l-johnsonGoogle:
"Gary Johnson"Parents
Sign in to add mentor| John P. Perkins | grad student | 1976 | University of Colorado HSC |
| Henry R. Bourne | post-doc | UCSF |
Children
Sign in to add trainee| Aaron C. Spalding | grad student | 2001 | University of Colorado, Denver |
| Andrea H. Bild | grad student | 2002 | University of Colorado, Denver |
| Katherine E. Lobel-Rice | grad student | 2002 | University of Colorado, Denver |
| James A. Witowsky | grad student | 2002 | University of Colorado, Denver |
| Lynn E. Heasley | post-doc | 1985-1991 | University Of Massachusetts Med Sch Worcester/National Jewish Research Ctr (Cell Biology Tree) |
| Anne M. Gardner | post-doc | 1992-1996 | University of Colorado, Denver |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Matkar S, East MP, Stuhlmiller TJ, et al. (2025) Kinome reprogramming of G2/M kinases and repression of MYCN contribute to superior efficacy of lorlatinib in ALK-driven neuroblastoma. Molecular Cancer Therapeutics |
| East MP, Sprung RW, Okumu DO, et al. (2024) Quantitative proteomic mass spectrometry of protein kinases to determine dynamic heterogeneity of the human kinome. Biorxiv : the Preprint Server For Biology |
| Berginski ME, Jenner MR, Joisa CU, et al. (2024) Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines. Peerj. 12: e17797 |
| Asquith CRM, East MP, Laitinen T, et al. (2024) Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships. European Journal of Medicinal Chemistry. 271: 116357 |
| Gomez SM, Drewry DH, Willson TM, et al. (2024) Illuminating function of the understudied druggable kinome. Drug Discovery Today. 103881 |
| Joisa CU, Chen KA, Beville S, et al. (2023) Combined kinome inhibition states are predictive of cancer cell line sensitivity to kinase inhibitor combination therapies. Biorxiv : the Preprint Server For Biology |
| Asquith CRM, Temme L, East MP, et al. (2022) Identification of 4-anilino-quin(az)oline as a cell active Protein Kinase Novel 3 (PKN3) inhibitor chemotype. Chemmedchem |
| East MP, Johnson GL. (2021) Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition. The Journal of Biological Chemistry. 101525 |
| Pucciarelli D, Angus SP, Huang B, et al. (2020) Nf1 mutant tumors undergo transcriptome and kinome re-modeling after inhibition of either mTOR or MEK. Molecular Cancer Therapeutics |
| Goulet DR, Foster JP, Zawistowski JS, et al. (2020) Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer. Molecular Cancer Research : McR |